Exelixis

Cabometyx Halts Trial Early in Neuroendocrine Tumors (ESMO 2023)

Cabometyx Shows Dramatic Benefits in Advanced Neuroendocrine Tumors (ESMO 2023)

Anika Sharma

ESMO 2023: LBA53 Exelixis made headlines last month when its Cabometyx exceeded expectations in the treatment of neuroendocrine tumors (NETs), ...

Exelixis, Insilico Medicine, LIB Therapeutics, licensing deal, artificial intelligence, ISM3091

Exelixis partners with AI company Insilico to discover new drugs, LIB sells China rights for PCSK9 drug

Anika Sharma

Exelixis, the pharmaceutical company recognized for its solid tumor medication Cabometyx, is adopting artificial intelligence (AI) to bolster its pipeline. ...

Cabometyx, pancreatic cancer, Clinical trial results, Exelixis, Neuroendocrine Tumors

Exelixis Celebrates Early End to Cabometyx Trial for Neuroendocrine Tumors due to Remarkable Efficacy

Anika Sharma

Exelixis, a drug developer, recently halted a cancer trial involving Cabometyx, their tyrosine kinase inhibitor, due to an overwhelming display ...

Roche, Exelixis, Ipsen, Cabometyx, Tecentriq, Prostate cancer

Resilient Triumph: Roche and Exelixis’ Tecentriq-Cabometyx Combination Shows Promise in Advanced Prostate Cancer After Past Challenges

Anika Sharma

After facing setbacks in clinical trials, the combination of Roche’s Tecentriq and Exelixis’ Cabometyx has achieved a breakthrough in treating ...

Exelixis and Teva Settle Cabometyx Patent Dispute, Allow Generic in 2031

Cabometyx patent battle is resolved by Exelixis and Teva with a 2031 generic license

SG Tylor

Source – Exelixis Exelixis, the company behind the successful cancer drug Cabometyx, has been actively defending its intellectual property. In ...